These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22911668)

  • 1. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
    Drake CG
    J Natl Cancer Inst; 2012 Sep; 104(18):1422; author reply 1422-3. PubMed ID: 22911668
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
    Kantoff PW; Higano CS; Small EJ; Whitmore JB; Frohlich MW; Schellhammer PF
    J Natl Cancer Inst; 2012 Jul; 104(14):1107-9; author reply 1109-12. PubMed ID: 22825556
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
    Gulley JL; Leitman SF; Dahut W; Schlom J
    J Natl Cancer Inst; 2012 Jul; 104(14):1106; author reply 1109-12. PubMed ID: 22825555
    [No Abstract]   [Full Text] [Related]  

  • 4. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
    Huber ML; Haynes L; Parker C; Iversen P
    J Natl Cancer Inst; 2012 Feb; 104(4):273-9. PubMed ID: 22232132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sipuleucel-T in metastatic castration-resistant prostate cancer: profile report.
    Plosker GL
    BioDrugs; 2011 Aug; 25(4):255-6. PubMed ID: 21815700
    [No Abstract]   [Full Text] [Related]  

  • 6. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
    Tanimoto T; Hori A; Kami M
    N Engl J Med; 2010 Nov; 363(20):1966; author reply 1967-8. PubMed ID: 21067392
    [No Abstract]   [Full Text] [Related]  

  • 7. Prostate cancer immunotherapy: the role for sipuleucel-T and other immunologic approaches.
    Arlen PM
    Oncology (Williston Park); 2011 Mar; 25(3):261-2. PubMed ID: 21548469
    [No Abstract]   [Full Text] [Related]  

  • 8. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
    Sartor O
    BJU Int; 2012 Jul; 110(2 Pt 2):E105. PubMed ID: 22176510
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm.
    Garcia JA; Dreicer R
    Oncology (Williston Park); 2011 Mar; 25(3):242-9. PubMed ID: 21548467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for advanced prostate cancer: a novel treatment option to improve survival.
    Peskin SR
    Manag Care; 2011 Sep; 20(9 Suppl 5):3-4, 6-11. PubMed ID: 22046617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
    Di Lorenzo G; Ferro M; Buonerba C
    BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
    Nabhan C
    N Engl J Med; 2010 Nov; 363(20):1966-7; author reply 1968. PubMed ID: 21067391
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
    Sims RB
    Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New treatments for metastic prostate cancer.
    Med Lett Drugs Ther; 2010 Sep; 52(1346):69-70. PubMed ID: 20814400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
    Wei XX; Fong L; Small EJ
    Expert Rev Vaccines; 2015; 14(12):1529-41. PubMed ID: 26488270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sipuleucel-T for the treatment of advanced prostate cancer.
    Frohlich MW
    Semin Oncol; 2012 Jun; 39(3):245-52. PubMed ID: 22595047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for castration-resistant prostate cancer.
    Sonpavde G; Kantoff PW
    Urol Clin North Am; 2012 Nov; 39(4):465-81. PubMed ID: 23084524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
    Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
    Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer.
    Holko P; Kawalec P
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):63-73. PubMed ID: 24224852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.
    Davis K; Wood S; Dill E; Fesko Y; Bitting RL; Harrison MR; Armstrong AJ; Moul JW; George DJ
    Clin J Oncol Nurs; 2015 Jun; 19(3):297-303. PubMed ID: 26000580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.